- Home
- ANAB vs JKS Comparison
ANAB vs JKS Comparison
Compare ANAB & JKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | JKS |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ANAB | JKS |
|---|---|---|
| Price | $47.66 | $27.31 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 12 | 4 |
| Target Price | ★ $60.18 | $19.49 |
| AVG Volume (30 Days) | 499.2K | ★ 802.6K |
| Earning Date | 02-26-2026 | 11-17-2025 |
| Dividend Yield | N/A | ★ 4.67% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $169,467,000.00 | ★ $9,641,756,390.00 |
| Revenue This Year | $135.51 | N/A |
| Revenue Next Year | N/A | $37.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.42 | N/A |
| 52 Week Low | $12.21 | $13.42 |
| 52 Week High | $52.47 | $31.88 |
Technical Indicators
Market Signals| Indicator | ANAB | JKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 49.71 |
| Support Level | $46.06 | $26.65 |
| Resistance Level | $50.00 | $28.78 |
| Average True Range (ATR) | 3.02 | 1.57 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 64.38 | 46.24 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.